|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.5 USD | +1.21% |
|
+11.11% | +7.30% |
| Apr. 04 | Transcript : VYNE Therapeutics Inc. - Special Call | |
| Feb. 29 | VYNE Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
VYNE Therapeutics Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 0.076 million compared to USD 0.006 million a year ago. Net loss was USD 6.19 million compared to USD 9.95 million a year ago.
Basic loss per share from continuing operations was USD 0.2 compared to USD 2.6 a year ago. Basic loss per share was USD 0.2 compared to USD 3.33 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +7.30% | 35.25M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
VYNE THERAPEUTICS INC. 
